MARKET

TVTX

TVTX

Travere Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

30.82
+1.12
+3.77%
After Hours: 30.82 0 0.00% 16:51 02/26 EST
OPEN
30.02
PREV CLOSE
29.70
HIGH
31.18
LOW
29.32
VOLUME
355.35K
TURNOVER
--
52 WEEK HIGH
33.09
52 WEEK LOW
8.98
MARKET CAP
1.80B
P/E (TTM)
-14.3804
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), EveryLife Foundation for Rare Diseases, Global Gen...
GlobeNewswire · 2d ago
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
Zacks.com · 4d ago
What's in the Cards for BioNTech (BNTX) This Earnings Season?
Zacks.com · 4d ago
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in February and March: SVB Leerink 10th Annual Global Healthc...
GlobeNewswire · 5d ago
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks.com · 5d ago
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks.com · 5d ago
Inovio (INO) to Report Q4 Earnings: What's in the Cards?
Zacks.com · 5d ago
Why Earnings Season Could Be Great for Travere Therapeutics (TVTX)
Zacks.com · 02/19 19:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TVTX. Analyze the recent business situations of Travere Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TVTX stock price target is 38.40 with a high estimate of 51.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 225
Institutional Holdings: 56.60M
% Owned: 96.65%
Shares Outstanding: 58.56M
TypeInstitutionsShares
Increased
47
4.79M
New
50
-1.36M
Decreased
39
3.16M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Director
Gary Lyons
President/Chief Executive Officer/Director
Eric Dube
Chief Financial Officer/Senior Vice President
Laura Clague
Senior Vice President/General Counsel/Secretary
Elizabeth Reed
Senior Vice President
William Rote
Other
Peter Heerma
Vice President
Casey Logan
Other
Noah Rosenberg
Director
Stephen Aselage
Independent Director
Roy Baynes
Independent Director
Suzanne Bruhn
Independent Director
Timothy Coughlin
Independent Director
Jeffrey Meckler
Independent Director
John Orwin
Independent Director
Sandra Poole
Independent Director
Ron Squarer
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About TVTX
Travere Therapeutics Inc., formerly Retrophin Inc., is a biopharmaceutical company. The Company specializing in identifying, developing and delivering therapies to people living with rare disease. It's pipeline includes sparsentan (RE-021), a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). Sparsentan is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A and a potent angiotensin receptor blocker (ARB). It's pipeline also includes also include OT-58, an investigational human enzyme replacement therapy. OT-58 is being developed for the treatment of classical homocystinuria (HCU). The Company's commercial products include Chenodal, Cholbam, Thiola and Thiola EC.

Webull offers kinds of Travere Therapeutics Inc stock information, including NASDAQ:TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.